Precigen, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Precigen, Inc.
5.26
+5.51%
vs ±21.3% implied · ×0.26
shaded = implied · ▲▼ = realized
Linked news
NewsPrecigen has 5 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceWe had selected Eversana, a leading provider of commercialization services to the global life sciences industry, to support launch strategy and commercialization of Papzimeos in the United States.
PGEN 10-Kaccession 0001356090-26-000009
SentenceIn addition, we announced a plan to continue PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement ("CRADA") with the National Cancer Institute ("NCI") in recurrent/metastatic cervical cancer and in newly diagnosed HPV-associated oropharyngeal cancer.
PGEN 10-Kaccession 0001356090-26-000009
SentenceWe have historically been controlled and principally funded by Randal J. Kirk, our Executive Chairman, and affiliates of Mr. Kirk, including Third Security.
PGEN 10-Kaccession 0001356090-26-000009
SentenceWe have historically been controlled and principally funded by Randal J. Kirk, our Executive Chairman, and affiliates of Mr. Kirk, including Third Security.
PGEN 10-Kaccession 0001356090-26-000009
SentenceSleeping Beauty is a non-viral transposon/transposase system licensed from the University of Texas MD Anderson Cancer Center that stably reprograms immune cells by inserting specific DNA sequences into their genome.
PGEN 10-Kaccession 0001356090-26-000009
Expected move
Inputs8Q avg ±10.2%·×0.67·cheap
straddle ±16.5%
spot 6.94exp Nov 20ATM strike 7ATM straddle 1.35IV 101%